Study guide

4.2 Individualized Treatment Planning & Molecular Tumor Boards

Advanced Oncology Certified Nurse Practitioner AOCNP

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction & Exam Overview

1.1 About the AOCNP Exam 1.2 How to Use This AOCNP Study Guide

2 Chapter 2: Cancer Continuum - Risk, Prevention & Screening

2.1 Cancer Risk Factors, At-Risk Populations & Health Disparities 2.2 Primary Prevention, Vaccination, Chemoprevention & Risk-Reducing Surgery 2.3 Cancer Screening & Early Detection Guidelines 2.4 Screening for Subsequent & Second Primary Malignancies 2.5 Hereditary Cancer Syndromes & Genetic Counseling

3 Chapter 3: Cancer Continuum - Assessment, Diagnosis & Staging

3.1 Diagnostic Workup, Tissue Biopsy & Biomarker Evaluation 3.2 Pathology Interpretation, Histology & Tumor Grading 3.3 Cancer Staging Systems (TNM) & Prognostication Models 3.4 Performance Status, Frailty & Geriatric Assessment

4 Chapter 4: Cancer Continuum - Planning, Coordination & Survivorship

4.1 Established Guidelines for Care & Categories of Evidence 4.2 Individualized Treatment Planning & Molecular Tumor Boards 4.3 Reproductive Planning & Fertility Preservation 4.4 Patient Navigation & Interprofessional Care Coordination 4.5 Survivorship Care Planning & Late Effects Management 4.6 Post-Treatment Surveillance for Cancer Recurrence

5 Chapter 5: Cancer Treatment - Antineoplastic Pharmacology & Chemotherapy

5.1 Antineoplastic Principles, Dosing & Dose Adjustments 5.2 Cytotoxic Chemotherapy Classes & Adverse Effect Management 5.3 Safe Administration, Handling & Infusion Toxicities 5.4 Oral Antineoplastic Therapy: Adherence, Interactions & Monitoring

6 Chapter 6: Cancer Treatment - Targeted, Immuno & Hormonal Therapies

6.1 Targeted Therapies, Tyrosine Kinase Inhibitors & ADCs 6.2 Cancer Immunotherapy, Checkpoint Inhibitors & CAR T-Cell Therapy 6.3 Endocrine & Hormonal Therapies in Oncology

7 Chapter 7: Cancer Treatment - Radiation, Surgery, Regional & Multimodal Therapy

7.1 Radiation Oncology Principles & Toxicity Management 7.2 Surgical Oncology, Perioperative Care & Reconstruction 7.3 Regional & Localized Therapy Administration 7.4 Multimodal Therapy & Treatment Sequencing 7.5 Complementary, Alternative & Integrative Therapies

8 Chapter 8: Cancer Treatment - Transplantation, Clinical Trials & Response

8.1 Hematopoietic Stem Cell Transplantation (HSCT) & Cell Therapy 8.2 Clinical Trials, Research Protocols & Response Evaluation (RECIST)

9 Chapter 9: Supportive Care - Pain & Controlled Substance Safety

9.1 Cancer Pain Assessment & Comprehensive Analgesic Management 9.2 Controlled Substance Safety & Opioid Stewardship 9.3 Nonpharmacologic & Integrative Symptom Interventions

10 Chapter 10: Supportive Care - Symptom & Comorbidity Management

10.1 Acute, Late & Long-Term Patterns of Treatment-Related Symptoms 10.2 Gastrointestinal Symptom Management (CINV, Mucositis, Diarrhea) 10.3 Hematologic & Neurologic Toxicity Management 10.4 Dermatologic, Metabolic & Fatigue Management 10.5 Cancer-Associated Thrombosis & Anticoagulation 10.6 Comorbid Conditions & Their Interaction With Cancer Treatment 10.7 Palliative Care, Hospice & End-of-Life Management

11 Chapter 11: Oncologic Emergencies

11.1 Superior Vena Cava Syndrome & Structural Emergencies 11.2 Spinal Cord Compression & Neurologic Emergencies 11.3 Metabolic Emergencies: Tumor Lysis Syndrome & Hypercalcemia of Malignancy 11.4 Febrile Neutropenia, Sepsis & Vesicant Extravasation 11.5 Cardiopulmonary & Airway Emergencies 11.6 Hematologic & Endocrine Emergencies: DIC, Leukostasis, Hyperviscosity & SIADH

12 Chapter 12: Psychosocial Issues

12.1 Psychosocial Assessment & Distress Screening in Oncology 12.2 Risk Factors & At-Risk Oncology Populations 12.3 Psychosocial & Emotional Sequelae of Disease and Treatment 12.4 Psychiatric & Psychosocial Comorbidities in Cancer Care 12.5 Caregiver Burden, Support & Community Resources

13 Chapter 13: Professional Practice & Roles of the APRN

13.1 APRN Scope of Practice, Prescriptive Authority & Standards of Care 13.2 Bioethics, Informed Consent & Quality Improvement in Oncology 13.3 Cultural Competence, Implicit Bias & Equitable Oncology Care 13.4 Accreditation Standards & Outcomes of APRN Practice 13.5 Competency Evaluation, Peer Review & Peer Education

4.2 Individualized Treatment Planning & Molecular Tumor Boards

Key Takeaways Explain This Topic AI

An individualized plan requires four inputs assembled together: clinical history and goals, pathology and biomarkers, laboratory and organ function, and radiologic disease extent.

Treatment intent must be named explicitly as curative, adjuvant, neoadjuvant, disease-control, or palliative, because intent determines how much toxicity is acceptable.

Actionability of a genomic finding is tiered: an on-label matched therapy outranks an off-label or trial-eligible alteration, which outranks a variant of unknown clinical significance.

Tumor-only sequencing can incidentally reveal a suspected germline variant, which requires confirmatory germline testing and genetic counseling rather than direct action on the tumor report.

Baseline organ-function testing must be exposure-specific: echocardiography before anthracyclines or HER2-directed therapy, pulmonary function with DLCO before bleomycin, audiometry before cisplatin, and creatinine clearance before renally cleared agents.

Last updated: August 2026

4.2 Individualized Treatment Planning & Molecular Tumor Boards

Blueprint focus: ONCC Domain I.B.4 — Individualized treatment planning based on history, pathology/biomarkers, laboratory, and radiologic results. This is the synthesis item on the blueprint: everything from Chapters 2 and 3 converges here into a plan.

The Four Inputs

A treatment plan is not a regimen selected from an algorithm. It is the intersection of four data streams.

1. Clinical history and patient goals. Age and functional status, comorbidity burden, prior antineoplastic exposure and cumulative doses, prior radiation fields, allergies, reproductive plans, social support, transportation, insurance and out-of-pocket exposure, and — most importantly — what the patient is trying to achieve.

2. Pathology and biomarkers. Histologic subtype and grade; immunohistochemistry; predictive biomarkers that select therapy (ER, PR, HER2, PD-L1, EGFR , ALK , BRAF , KRAS G12C , MSI-H/dMMR, NTRK ); prognostic biomarkers that estimate outcome independent of therapy (Ki-67, TP53 , 17p deletion); and multigene recurrence assays.

3. Laboratory and organ function. Complete blood count, comprehensive metabolic panel, calculated creatinine clearance, hepatic function, tumor markers where validated, hepatitis B and C and HIV serologies before immunosuppressive therapy, pregnancy testing, and pharmacogenomic screens such as DPYD before fluoropyrimidines and UGT1A1 before irinotecan.

4. Radiologic disease extent. Stage, sites of disease, whether disease is resectable, whether an organ is threatened, and — critically — baseline measurements that will later define response.

Step 1: Name the Treatment Intent

Before selecting any drug, state the intent in the chart. This single sentence determines how much toxicity is acceptable.

  • Intent Definition Toxicity tolerance
  • Curative Eradication of all disease is the goal High; dose intensity is preserved wherever possible

Neoadjuvant Given before definitive local therapy to downstage, enable organ preservation, and test in vivo sensitivity High, but must not preclude surgery

Adjuvant Given after definitive local therapy to eradicate micrometastatic disease in a patient with no measurable tumor Moderate; the patient is already disease-free, so harms weigh heavily

Disease control Incurable disease treated to prolong survival and delay progression Moderate; balance duration of benefit against quality of life

Palliative Symptom relief is the objective Low; any regimen that worsens quality of life fails its own purpose

Adjuvant intent deserves special care because the patient feels well. Every adverse effect is a harm imposed on someone who has no symptoms, which is why absolute benefit — not relative risk reduction — must be the number discussed.

Step 2: The Molecular Tumor Board

Comprehensive genomic profiling generates far more findings than actionable ones. The molecular tumor board exists to convert a sequencing report into a decision. Membership typically includes medical oncology, pathology and molecular pathology, clinical genetics, pharmacy, bioinformatics, clinical research, and the oncology APRN.

Tiering a genomic finding

Tier Finding Action

Highest actionability Alteration with an FDA-approved, on-label matched therapy for this tumor type (for example EGFR exon 19 deletion in NSCLC) Match therapy directly

High Alteration with a tumor-agnostic approval (MSI-H/dMMR, TMB-high, NTRK fusion, BRAF V600E ) Match therapy across histologies

Moderate Alteration approved in a different tumor type, or with compelling trial data Seek a clinical trial first; off-label use requires justification and payer navigation

Low Alteration of biological interest without clinical data Do not act; record for future reassessment

Not actionable Variant of uncertain significance Do not use to select therapy or surgery; reassess as classification evolves

Two traps the exam likes

A negative liquid biopsy does not exclude a driver. Circulating tumor DNA has a high positive predictive value but a substantial false-negative rate when a tumor sheds little DNA. A negative plasma result in a patient who has not been tissue-tested must be followed by tissue sequencing.

A tumor-only report can flag a germline variant. When somatic sequencing reports a BRCA1/2 , mismatch repair, or TP53 alteration at a variant allele fraction suggesting germline origin, the correct action is confirmatory germline testing with genetic counseling , not an assumption either way. Somatic and germline findings have different implications for relatives and for risk-reducing surgery.

Step 3: Baseline Organ-Function Testing Matched to Planned Exposure

Planned exposure Required baseline Why

Anthracycline or HER2-directed therapy Echocardiogram or MUGA for LVEF Cumulative and reversible cardiotoxicity respectively

  • Bleomycin Pulmonary function tests with DLCO Pulmonary fibrosis is dose-related and irreversible
  • Cisplatin Audiometry and creatinine clearance Irreversible high-frequency hearing loss and nephrotoxicity
  • Carboplatin Creatinine clearance Calvert dosing depends directly on GFR
  • Fluoropyrimidine DPYD genotype Prevents fatal toxicity in deficient patients
  • Irinotecan UGT1A1 genotype where indicated Prevents severe neutropenia and diarrhea

Rituximab or other B-cell-depleting therapy Hepatitis B surface antigen and core antibody Reactivation risk demands prophylaxis

Immune checkpoint inhibitor Thyroid function, cortisol if symptomatic, baseline glucose Establishes the baseline against which endocrine irAEs are judged

  • Any gonadotoxic therapy Pregnancy test, fertility discussion See Section 4.3
  • Step 4: Modify for the Person, Not Only the Tumor

Renal impairment — substitute carboplatin for cisplatin; adjust or avoid high-dose methotrexate; recalculate all renally cleared doses.

Hepatic impairment — reduce anthracyclines, vinca alkaloids, and taxanes according to bilirubin.

Cardiac disease — cap or avoid anthracyclines; monitor LVEF more frequently with HER2-directed therapy; consider anthracycline-free regimens.

Autoimmune disease — checkpoint inhibitors are not absolutely contraindicated but require explicit risk discussion and rheumatology co-management.

Reproductive plans — fertility preservation must precede the first gonadotoxic dose, not follow it.

Practical feasibility — a weekly infusion regimen is not equivalent to an oral regimen for a patient who lives three hours from the infusion center and cannot drive.

Step 5: Document the Plan So It Can Be Executed

A usable plan states the regimen and dose basis, the intent, the number of planned cycles, the response assessment interval and modality, the specific toxicities being monitored and how, the supportive care ordered prospectively (antiemetics, growth factors, prophylaxis), the criteria that would trigger dose reduction or a change of plan, and the patient's stated goals in their own words. Anything less leaves the next clinician guessing.

Loading diagram... Building an Individualized Treatment Plan